TY  - CHAP
M1  - Book, Section
TI  - Benign Prostatic Hyperplasia
A1  - Lee, Mary
A1  - Sharifi, Roohollah
A2  - Chisholm-Burns, Marie A.
A2  - Schwinghammer, Terry L.
A2  - Malone, Patrick M.
A2  - Kolesar, Jill M.
A2  - Bookstaver, P. Brandon
A2  - Lee, Kelly C.
PY  - 2022
T2  - Pharmacotherapy Principles & Practice, 6e
AB  - LEARNING  OBJECTIVESUpon  completion  of  the  chapter,  the  reader  will  be  able  to:Explain  the  pathophysiology  of  benign  prostatic  hypertrophy  (BPH).Recognize  the  symptoms  and  signs  of  BPH.List  the  desired  treatment  outcomes  for  BPH.Identify  factors  that  guide  selection  of  a  particular  α1-adrenergic  antagonist  for  an  individual  patient.Compare  and  contrast  α1-adrenergic  antagonists,  5α-reductase  inhibitors,  anticholinergic  agents,  tadalafil,  and  mirabegron  in  terms  of  mechanism  of  action,  treatment  outcomes,  adverse  effects,  and  interactions.Describe  the  indications,  advantages,  and  disadvantages  of  a  combination  drug  regimen  that  includes  an  α1-adrenergic  antagonist  and  5α-reductase  inhibitor.Describe  the  indications  for  surgical  intervention.Apply  the  patient  care  process  to  develop  an  individualized  treatment  plan.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/10/06
UR  - ppp.mhmedical.com/content.aspx?aid=1187023743
ER  -